ReGenesys
Gaston Geenslaan 1
3001 Heverlee
BE
ReGenesys
Foundation date
17/10/2005
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
ReGenesys BV is a wholly-owned subsidiary of Athersys, Inc. (NASDAQ: ATHX), a biotechnology company in Cleveland, Ohio, U.S.A., that is developing MultiStem® cell therapy, a patented, adult-derived, “off-the-shelf” stem cell product initially for disease indications in the neurological, cardiovascular, inflammatory and immune areas. Athersys has several ongoing clinical trials to evaluate its MultiStem product candidate.
Upcoming events
All events-
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB -
1212 '22
Type 2 Immunity in Homeostasis and Disease (2nd edition)
Event by: VIB -
2911 '22
BioFIT 2022
Event by: Eurasanté
Latest news
More news-
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
13 hours ago
Read more
-
Indigo Diabetes announces first participant enrolled in the SHINE clinical trial
Thursday September 29th 2022
Read more
-
FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome
Tuesday September 27th 2022
Read more